MIT Selects Privo Technologies To Showcase the Company’s Groundbreaking Cancer Therapy in Japan and Korea.

Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its nano-engineered platform technology and its product PRV111 for oral cancer at two major events in Asia. In January 2019, Privo will proudly represent the kind of innovation and entrepreneurship Massachusetts Institute of Technology (MIT) enables when CEO Manijeh Goldberg will introduce Privo’s research and products at the 2019 MIT Japan Conference in Tokyo, as well as at the Korea Symposium in Seoul, South Korea.

Privo will welcome this opportunity to introduce its groundbreaking cancer therapy to the Asian market and establish collaborative partnerships with industry leaders in Japan as well as Korea.

Share this post

Contact Us
close slider

Contact Us